PT - JOURNAL ARTICLE AU - Ebneabbasi, Amir AU - Afshani, Mortaza AU - Seyed-Ahmadi, Arman AU - Warrier, Varun AU - Bethlehem, Richard A.I. AU - Rittman, Timothy TI - How Do Neurotransmitter Pathways Contribute to Neuroimaging Phenotypes? AID - 10.1101/2024.04.26.24305395 DP - 2024 Jan 01 TA - medRxiv PG - 2024.04.26.24305395 4099 - http://medrxiv.org/content/early/2024/04/29/2024.04.26.24305395.short 4100 - http://medrxiv.org/content/early/2024/04/29/2024.04.26.24305395.full AB - Neuroimaging could accurately reflect human behaviour in health and disease, but the mechanism by which image-derived phenotypes correspond to neurotransmitter systems remains uncertain. Prior studies have explored spatial correlations between neuroimaging phenotypes and positron emission tomography radiotracers. However, the influence of neurotransmitters goes beyond the receptors/transporters, influencing a wider array of intracellular components as pivotal parts of neurotransmitter pathways. Here, we used unsupervised learning to understand how the brain maps of healthy function (i.e., magnetoencephalography frequency-specific power) and abnormal structure (i.e., disorder-specific cortical thickness) are closely anchored to underlying neurotransmitter pathways assessed by gene expression data. To do this, we used large-scale datasets of the Human Connectome Project (HCP), Enhancing NeuroImaging Genetics through Meta-Analysis (ENIGMA) and Allen Human Brain Atlas (AHBA). We considered spatial and random gene null models to mitigate false positives. We replicate our analyses using different gene stability thresholds. This analytic approach paves the way for personalised medicine and advanced biomarkers.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data was readily accessible prior to the initiation of the study, and we shared download links for easy retrieval. Neurotransmitter-specific gene sets(http://amigo.geneontology.org/amigo/landing) Tissue-specific genes(https://gtexportal.org/home/) Neurodevelopmental genes(http://www.brainspan.org) Allen Human Brain Atlas (AHBA)(https://human.brain-map.org/) Neuropsychological decoding (https://neurosynth.org/) Case-control cortical thickness maps(https://enigma-toolbox.readthedocs.io/en/latest/) Frequency-specific power maps(https://github.com/netneurolab/neuromaps) (https://www.humanconnectome.org/study/hcp-young-adult) GWAS summary statistics(https://pgc.unc.edu/for-researchers/download-results/)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript